Evommune Presents Positive Clinical Results of its MRGPRX2 Antagonist (EVO756) at the 7th GA²LEN Global Urticaria Forum
Proof-of-concept trial of EVO756 in 132 subjects, demonstrated an excellent safety profile, robust efficacy, and a pharmacokinetic profile supporting once-daily oral dosingThe data suggest the potential of EVO756 as a